PSMA PET Imaging Enhances Detection of Bone Metastases in Prostate Cancer Patients

Recent findings underscore the efficacy of prostate-specific membrane antigen (PSMA) PET imaging in identifying bone metastases that are often missed by conventional imaging methods in prostate cancer patients. This advancement, presented at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting, is crucial due to the significant impact of bone metastases on patients' prognosis and long-term survival.

Prostate cancer typically spreads to bones, which are traditionally detected with bone scans and CT scans. However, these techniques can overlook small cancer deposits that might alter a patient's prognosis. PSMA PET, utilizing a radioactive tracer targeting a protein on prostate cancer cells, has proven more sensitive, establishing itself as the gold standard for staging prostate cancer in leading cancer centers.

"PSMA PET scans are effective for detecting bone metastases, but data on overall outcomes have been lacking," stated Surekha Yadav, MBBS, from the University of California, San Francisco. A retrospective study led by Yadav examined outcomes in 36 patients with 1 to 5 bone lesions detected by PSMA PET, while conventional imaging appeared normal.

The study revealed that over 80% of these patients had normal results on conventional scans, highlighting the limitations of traditional methods. Among the same cohort, those with bone lesions identified by PSMA PET had over five times the risk of progressing to treatment-resistant cancer and nearly four times the risk of mortality compared to 984 patients without bone metastases on PSMA PET.

Decisions regarding early treatment are crucial and can have lasting effects, as Yadav emphasizes. "Our study demonstrates that patients whose bone metastases are detected by PSMA PET are not in a gray zone. Their cancer progresses aggressively, despite conventional imaging suggesting otherwise." This illustrates the potential for mismanagement when bone scans fail to detect metastases.

PSMA PET is already approved by the FDA and accessible at major academic centers, such as the University of California, San Francisco, and the University of California, Los Angeles. Yadav added, "This research shifts the focus to how results are utilized in treatment planning, bridging a major knowledge gap in managing prostate cancer effectively."

In conclusion, PSMA PET provides valuable insights for oncologists, presenting a more comprehensive picture of cancer spread, which is vital for optimizing treatment strategies and improving outcomes for prostate cancer patients.